Uri Geiger
About Uri Geiger
Dr. Uri Geiger (age 57) is Chairman of the Board of STRATA Skin Sciences (SSKN) and has served on the Board since 2018. He co‑founded and is Managing Partner of Accelmed, a medical device private equity firm (founded 2009), and previously served as CEO of Exalenz Bioscience and GalayOr Networks; he holds a doctorate from Columbia University’s Center for Law & Economics and has authored books on venture capital and capital markets . He is not listed among SSKN’s independent directors in the company’s proxy; the proxy identifies Christina Allgeier, Samuel Rubinstein, and Dr. Irit Yaniv as independent, implying Dr. Geiger is not independent .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| STRATA Skin Sciences (SSKN) | Chairman of the Board | 2018–present | Board leadership (non-committee), chairs Board |
| Cogentix Medical | Chairman of the Board | Nov 2016–Apr 2018 (until sale) | Led through sale transaction |
| Exalenz Bioscience | Chief Executive Officer | May 2006–Dec 2008 | CEO leadership |
| GalayOr Networks | Co‑founder & CEO | 2001–2003 | Founder-CEO |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| Accelmed Partners | Co‑Founder & Managing Partner | 2009–present | Controls voting/investment decisions of Accelmed Partners’ SSKN holdings alongside Accelmed GP; see ownership footnote |
| NeuroPace, Inc. (public) | Director | Since Jan 2023 | Medical device company focused on epilepsy |
| Minerva Surgical, Inc. (public) | Director | Since Feb 2023 | Medical device company focused on uterine healthcare |
| Tel Aviv University (Recanati) | Former Adjunct Professor | Prior | Lectured on PE/VC; authored books |
Board Governance
- Structure and independence: Board has Audit and Compensation/Nominating & Governance (C/N/G) Committees; independent directors on both committees. Dr. Geiger (Chairman) does not sit on Audit or C/N/G; committees consist of Allgeier (Audit Chair), Rubinstein (C/N/G Chair), and Yaniv; these three are designated independent .
- Meetings and attendance: In the last fiscal year, the Board met 12 times; Audit met 7 times; C/N/G met 4 times. All directors attended at least 75% of the aggregate meetings of the Board and committees on which they served. The company encourages directors to attend the annual meeting, and each director then in office attended the 2024 annual meeting .
| Committee | Members | Chair | Notes |
|---|---|---|---|
| Audit | Allgeier; Rubinstein; Yaniv | Allgeier (financial expert) | Oversees financial reporting, auditor engagement, related‑party approvals |
| Compensation/Nominating & Governance | Rubinstein; Yaniv; Allgeier | Rubinstein | Director pay, equity plans, nominations, succession, independence oversight |
Fixed Compensation
| Component | Amount | Period/Notes |
|---|---|---|
| Board Chair Cash Retainer | $70,250 | Director fee schedule (Board chair does not serve on committees) |
| Committee Fees | $0 | Chair does not serve on committees |
| Fees Earned (Dr. Geiger) | $72,687 | Reported for year ended Dec 31, 2024; paid to Accelmed due to partnership policy |
Fees paid on behalf of Dr. Geiger were paid to Accelmed because Accelmed’s partnership agreement precludes the receipt of any equity .
Performance Compensation
| Component | Grant details | Value/Terms | Notes |
|---|---|---|---|
| Stock Awards (RSUs/DSUs) | None for Dr. Geiger | $0 | Equity not received due to Accelmed partnership policy |
| Option Awards | None for Dr. Geiger | $0 | New independent Board members get 20,000 options one‑time; not applicable to Geiger |
| Performance Metrics | N/A | — | No performance‑conditioned director pay disclosed |
Other Directorships & Interlocks
| Person/Entity | Relationship to SSKN | Interlock/Overlap | Governance Consideration |
|---|---|---|---|
| Accelmed Partners | Dr. Geiger is Managing Partner; Accelmed controls SSKN shares | Fees for Geiger’s director service paid to Accelmed; Accelmed holds significant SSKN stake with Geiger in control roles | Potential influence and conflict risk; related‑party oversight by Audit Committee |
| Dr. Irit Yaniv | SSKN Director | Partner at Accelmed Ventures (since 2012) | Multiple Accelmed‑affiliated directors on SSKN Board |
| John Gillings | SSKN CAO | Previously worked in private equity with Accelmed Partners | Management overlap with Accelmed |
| NeuroPace, Minerva Surgical | Dr. Geiger is a director | External public boards | Time commitments; network leverage |
Expertise & Qualifications
- Entrepreneurial and investing track record building medical device businesses; former CEO roles in Exalenz and GalayOr; chaired Cogentix through sale .
- Capital markets and governance expertise (Wall Street experience; Columbia Law & Economics doctorate; business school adjunct on PE/VC; author of “Startup Companies and Venture Capital” and “From Concept to Wall Street”) .
Equity Ownership
| Holder | Shares Beneficially Owned | % of Outstanding | Notes |
|---|---|---|---|
| Uri Geiger (footnote 3) | 1,441,835 | 34.55% | As of March 31, 2025; based on 4,171,161 shares outstanding |
| Accelmed Partners LP (footnote 3) | 1,211,262 | 34.55% | Separate line item in table; footnote states Accelmed holds 1,441,836 shares; Dr. Geiger/Accelmed disclaim beneficial ownership except to extent of pecuniary interest |
Footnote clarifies Accelmed Partners GP and Dr. Geiger (via Accelmed Management Ltd.) have voting and investment control over Accelmed’s SSKN securities; Dr. Geiger and Accelmed disclaim beneficial ownership except to the extent of pecuniary interest .
No director stock ownership guidelines, pledging, or hedging disclosures specific to Dr. Geiger were provided in the proxy excerpts reviewed .
Related‑Party & Conflicts
- Director fees: Dr. Geiger’s fees ($72,687, 2024) were paid to Accelmed due to partnership restrictions against receiving equity; he received no director equity .
- Significant ownership/control: Accelmed’s large SSKN stake is subject to voting/investment control by entities managed by Dr. Geiger; he disclaims beneficial ownership except to pecuniary interest .
- Board/management overlap: Another director (Dr. Yaniv) is an Accelmed Ventures partner and the Company’s CAO previously worked with Accelmed Partners, indicating potential influence channels to monitor .
- Oversight: Audit Committee is responsible for reviewing and approving related‑party transactions per charter .
Insider Filings / Trading
| Item | Disclosure |
|---|---|
| Section 16(a) compliance | Company states that, for FY 2024, all Section 16(a) filing requirements for officers, directors, and >10% holders were met, based on reviews and representations |
Governance Assessment
- Positives
- Experienced medtech investor/operator with prior chair and CEO roles; relevant capital markets expertise and network .
- Active board cadence and committee structure; all directors met at least 75% attendance; independent directors chair both key committees; audit chair designated financial expert .
- Concerns / RED FLAGS
- Concentrated influence: Accelmed’s significant ownership and Dr. Geiger’s control roles create potential conflicts of interest; he is not listed as an independent director .
- Alignment gap: No director equity for Dr. Geiger due to Accelmed policy (fees paid to Accelmed), potentially reducing direct equity alignment versus typical director pay practices; cash‑only compensation of $72,687 in 2024 .
- Interlocks: Additional Accelmed affiliations on the Board (Dr. Yaniv) and among management (CAO prior role at Accelmed Partners) may concentrate influence and warrant heightened related‑party oversight .
- Share reserve expansion: Proxy seeks a 520,000‑share increase to the 2016 Omnibus Plan; while not specific to director pay, it elevates equity program scope; change‑in‑control provisions allow accelerated vesting (plan‑wide governance consideration) .
Overall: Geiger brings deep sector and deal experience but exhibits elevated conflict risk due to Accelmed’s ownership/control, his non‑independence, and cash‑only director pay routed to Accelmed. Sustained scrutiny of related‑party approvals, independent committee leadership, and director engagement remains critical .
Notes on Data Sources
- Primary source: SSKN DEF 14A (Oct 30, 2025) for biography, governance, director compensation, ownership, and equity plan details .
- Annual meeting vote results (context): 8‑K Item 5.07 (Oct 30, 2024) confirms election of Dr. Geiger and director slate .
- Section 16 compliance and management overlaps: DEF 14A .